Conference report - Protein kinase inhibitors in cancer treatment: Mixing and matching?

MedGenMed Medscape General Medicine

Volumn 6, Issue 2, 2004, Pages

  Novak, Kris ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; ABELSON KINASE; BEVACIZUMAB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEFITINIB; GELDANAMYCIN; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PERTUZUMAB; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; RAF PROTEIN; SORAFENIB; TRASTUZUMAB;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CARCINOGENESIS; CELL FUNCTION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; CONFERENCE PAPER; DISEASE MODEL; DRUG BIOAVAILABILITY; DRUG TARGETING; DRUG TOLERABILITY; ENZYME ACTIVITY; HEART INJURY; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG CANCER; LUNG HEMORRHAGE; METASTASIS; NONHUMAN; PROTEIN FOLDING; SIDE EFFECT; SIGNAL TRANSDUCTION;

EID: 25144492221     PISSN: None     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (22)

1. Wittes R. A clinical perspective on the future of kinase-targeted therapies. Program and abstracts of the Keystone Symposium Protein Kinases and Cancer: The Promise of Molecular Based Therapies; February 24-29, 2004; Lake Tahoe, California.
2. Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 1. J Clin Oncol. 2004;22:777-784.
3. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2. J Clin Oncol. 2004;22:785-794.
4. Arteaga CL. Predictors of response and resistance to ErbB tyrosine kinase inhibitors. Program and abstracts of the Keystone Symposium Protein Kinases and Cancer: The Promise of Molecular Based Therapies; February 24-29, 2004; Lake Tahoe, California.
5. Arteaga CL. EGF receptor as a therapeutic target: patient selection and mechanisms of resistance to receptor-targeted drugs. J Clin Oncol. 2003;21(23 suppl):289s-291s.
6. Arteaga CL. Inhibiting tyrosine kinases: successes and limitations. Cancer Biol Ther. 2003;2(4 suppl 1):S79-S83.
7. Slikowski M. Target ligand-activated ErbB2/HER2 in solid tumors. Program and abstracts of the Keystone Symposium Protein Kinases and Cancer: The Promise of Molecular Based Therapies; February 24-29, 2004; Lake Tahoe, California.
8. Spigel DR, Burstein HJ. Trastuzumab regimens for HER2-overexpressing metastatic breast cancer. Clin Breast Cancer. 2003;4:329-337.
9. Hendriks BS, Opresko LK, Wiley HS, Lauffenburger D. Coregulation of epidermal growth factor receptor/human epidermal growth factor receptor 2 (HER2) levels and locations: quantitative analysis of HER2 overexpression effects. Cancer Res. 2003;63:1130-1137.
10. Marais R. B-Raf mutations in human cancer: implications for development of improved therapies. Program and abstracts of the Keystone Symposium Protein Kinases and Cancer: The Promise of Molecular Based Therapies; February 24-29, 2004; Lake Tahoe, California.
11. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949-954.
12. Wellbrock C, Garnett M, Marais R. IL-16 B-Raf in melanoma. Pigment Cell Res. 2003;16:579.
13. Sebolt-Leopold. Attractiveness of targeting MEK for anticancer drug development. Program and abstracts of the Keystone Symposium Protein Kinases and Cancer: The Promise of Molecular Based Therapies; February 24-29, 2004; Lake Tahoe, California.
14. Allen LF, Sebolt-Leopold J, Meyer MB. CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK). Semin Oncol. 2003;30(5 suppl 16):105-116.
15. Sawyers C. Clinical reality: How do oncologists screen for signaling abnormalities? Program and abstracts of the Keystone Symposium Protein Kinases and Cancer: The Promise of Molecular Based Therapies; February 24-29, 2004; Lake Tahoe, California.
16. Shah NP, Sawyers CL. Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias. Oncogene. 2003;22:7389-7395.
17. Mellinghoff IK, Sawyers CL. The emergence of resistance to targeted cancer therapeutics. Pharmacogenomics. 2002;3:603-623.
18. Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003;348:1201-1214.
19. Workman P. Drugging the cancer chaperone: Laboratory and clinical advances in targeting heat shock protein 90 (Hsp90). Program and abstracts of the Keystone Symposium Protein Kinases and Cancer: The Promise of Molecular Based Therapies; February 24-29, 2004; Lake Tahoe, California.
20. Banerji U, Judson I, Workman P. The clinical applications of heat shock protein inhibitors in cancer - present and future. Curr Cancer Drug Targets. 2003;3:385-390.
21. Neckers L, Ivy SP. Heat shock protein 90. Curr Opin Oncol. 2003;15:419-424.
22. Solit DB, Scher HI, Rosen N. Hsp90 as a therapeutic target in prostate cancer. Semin Oncol. 2003;30:709-716.